Phathom Pharmaceuticals, Inc. PHAT
We take great care to ensure that the data presented and summarized in this overview for Phathom Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PHAT
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$91 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$67.2 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$52.8 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$36.9 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$31.5 Million9.52% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$26.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.7MShares$24.3 Million0.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT2.58MShares$23.2 Million0.08% of portfolio
-
Woodline Partners LP San Francisco, CA2.57MShares$23.2 Million0.42% of portfolio
-
Nea Management Company, LLC Timonium, MD1.96MShares$17.6 Million2.71% of portfolio
Latest Institutional Activity in PHAT
Top Purchases
Top Sells
About PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Insider Transactions at PHAT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
Molly Henderson CFO and CBO |
SELL
Open market or private sale
|
Direct |
1,291
-1.3%
|
$10,328
$8.0 P/Share
|
|
Dec 19
2024
|
Azmi Nabulsi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,118
-0.47%
|
$8,944
$8.0 P/Share
|
|
Dec 13
2024
|
Asit Parikh |
BUY
Open market or private purchase
|
Direct |
10,000
+11.7%
|
$80,000
$8.12 P/Share
|
|
Dec 13
2024
|
Frank Karbe |
BUY
Open market or private purchase
|
Direct |
12,500
+17.99%
|
$87,500
$7.93 P/Share
|
|
Jul 15
2024
|
Terrie Curran President and Chief Executive |
SELL
Open market or private sale
|
Direct |
33,848
-8.22%
|
$372,328
$11.72 P/Share
|
|
Jul 15
2024
|
Molly Henderson CFO and CBO |
SELL
Open market or private sale
|
Direct |
4,325
-4.17%
|
$47,575
$11.72 P/Share
|
|
Jul 15
2024
|
Azmi Nabulsi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,901
-4.34%
|
$119,911
$11.72 P/Share
|
|
May 31
2024
|
Azmi Nabulsi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+2.92%
|
-
|
|
May 31
2024
|
Molly Henderson CFO and CBO |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+6.8%
|
-
|
|
May 29
2024
|
Frank Karbe |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+35.97%
|
$250,000
$10.16 P/Share
|
|
May 23
2024
|
Asit Parikh |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+13.82%
|
-
|
|
May 23
2024
|
James N Topper |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+24.65%
|
-
|
|
May 23
2024
|
Heidi Fields |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+35.0%
|
-
|
|
May 23
2024
|
Michael F Cola |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+26.38%
|
-
|
|
May 23
2024
|
Frank Karbe |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+35.0%
|
-
|
|
May 23
2024
|
Mark Stenhouse |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+35.0%
|
-
|
|
May 23
2024
|
David A Socks |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+35.0%
|
-
|
|
Apr 08
2024
|
Molly Henderson CFO and CBO |
SELL
Open market or private sale
|
Direct |
3,435
-3.48%
|
$37,785
$11.1 P/Share
|
|
Mar 22
2024
|
Terrie Curran President and Chief Executive |
SELL
Open market or private sale
|
Direct |
16,851
-3.94%
|
$151,659
$9.11 P/Share
|
|
Jan 24
2024
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,703,703
-49.65%
|
$29,629,624
$8.1 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 114K shares |
|---|---|
| Open market or private purchase | 22.5K shares |
| Open market or private sale | 3.78M shares |
|---|